COLO-B Stock Analysis: Coloplast | CO
Medical Instruments & Supplies | CO, Denmark | Market Cap: 92.964m DKK | 12M Return: -21% | DK0060448595 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 142M
EPS Trend: -69.7%
Qual. Beats: 0
Rev. Trend: 93.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Coloplast A/S is a Danish multinational medical device company founded in 1954 and headquartered in Humlebæk, Denmark. It develops and sells intimate healthcare products and services across five business segments: Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics, with operations spanning Denmark, the United States, the United Kingdom, France, and other international markets.
The companys product portfolio covers ostomy care solutions (including the SenSura Mio and Brava brands), continence care products (such as SpeediCath catheters and the Peristeen transanal irrigation system), wound dressings (Biatain Silicone and Comfeel lines), interventional urology products for conditions like erectile dysfunction and urinary incontinence, as well as voice and respiratory care solutions including the Provox voice prosthesis and Tracoe tracheostomy products.
As a player in the global medical devices industry, Coloplast operates a diversified business model focused on chronic and intimate care categories that typically generate recurring demand driven by long-term patient needs. Its classification within the Health Care Equipment sub-industry reflects its reliance on product-driven revenue from specialized medical supplies sold to patients, healthcare providers, and hospitals worldwide.
- Chronic Care and Continence Care drive organic revenue growth
- Wound Care pricing pressure squeezes margins amid competition
- Atos Medical and Kerecis acquisitions expand high-growth segments
| Net Income: 2.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.92 > 1.0 |
| NWC/Revenue: 13.14% < 20% (prev 0.01%; Δ 13.13% < -1%) |
| CFO/TA 0.16 > 3% & CFO 7.67b > Net Income 2.76b |
| Net Debt (24.0b) to EBITDA (11.7b): 2.04 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.4m) vs 12m ago -0.01% < -2% |
| Gross Margin: 58.50% > 18% (prev 67.55%; Δ -9.05% > 0.5%) |
| Asset Turnover: 59.99% > 50% (prev 58.20%; Δ 1.79% > 0%) |
| Interest Coverage Ratio: 10.55 > 6 (EBIT TTM 7.35b / Interest Expense TTM 697.0m) |
| A: 0.08 (Total Current Assets 10.4b - Total Current Liabilities 6.66b) / Total Assets 46.9b |
| B: 0.31 (Retained Earnings 14.4b / Total Assets 46.9b) |
| C: 0.16 (EBIT TTM 7.35b / Avg Total Assets 47.4b) |
| D: 0.40 (Book Value of Equity 13.4b / Total Liabilities 33.6b) |
| Altman-Z'' = 2.98 = A |
| DSRI: 0.93 (Receivables 5.07b/5.33b, Revenue 28.4b/27.9b) |
| GMI: 1.15 (GM 67.55% / 58.50%) |
| AQI: 0.95 (AQ_t 0.61 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 28.4b / 27.9b) |
| TATA: -0.10 (NI 2.76b - CFO 7.67b) / TA 46.9b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at DKK 435.90 with a total of 311,870 shares traded. Over the past week, the price has changed by +5.67%, over one month by +0.90%, over three months by +8.84% and over the past year by -21.00%.
Current recommended Stop Loss: 411.80 (which is 5.5% or 2.4 ATR below the current price).
Coloplast has no consensus analysts rating.
P/E Trailing = 33.6735
P/E Forward = 15.5763
P/S = 3.2686
P/B = 7.0745
P/EG = 1.0725
Revenue TTM = 28.4b DKK
EBIT TTM = 7.35b DKK
EBITDA TTM = 11.7b DKK
Long Term Debt = 20.2b DKK (from longTermDebt, last quarter)
Short Term Debt = 2.88b DKK (from shortTermDebt, last quarter)
Debt = 24.8b DKK (from shortLongTermDebtTotal, last quarter) + Leases 969.0m
Net Debt = 24.0b DKK (calculated: Debt 24.8b - CCE 817.0m)
Enterprise Value = 117b DKK (93.0b + Debt 24.8b - CCE 817.0m)
Interest Coverage Ratio = 10.55 (Ebit TTM 7.35b / Interest Expense TTM 697.0m)
EV/FCF = 18.65x (Enterprise Value 117b / FCF TTM 6.27b)
FCF Yield = 5.36% (FCF TTM 6.27b / Enterprise Value 117b)
FCF Margin = 22.04% (FCF TTM 6.27b / Revenue TTM 28.4b)
Net Margin = 9.71% (Net Income TTM 2.76b / Revenue TTM 28.4b)
Gross Margin = 58.50% ((Revenue TTM 28.4b - Cost of Revenue TTM 11.8b) / Revenue TTM)
Gross Margin QoQ = 66.73% (prev 42.95%)
Tobins Q-Ratio = 2.49 (Enterprise Value 117b / Total Assets 46.9b)
Interest Expense / Debt = 2.81% (Interest Expense 697.0m / Debt 24.8b)
Taxrate = 30.51% (1.21b / 3.98b)
NOPAT = 5.11b (EBIT 7.35b * (1 - 30.51%))
Current Ratio = 1.56 (Total Current Assets 10.4b / Total Current Liabilities 6.66b)
Debt / Equity = 1.85 (Debt 24.8b / totalStockholderEquity, last quarter 13.4b)
Debt / EBITDA = 2.04 (Net Debt 24.0b / EBITDA 11.7b)
Debt / FCF = 3.82 (Net Debt 24.0b / FCF TTM 6.27b)
Total Stockholder Equity = 14.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.83% (Net Income 2.76b / Total Assets 46.9b)
RoE = 19.69% (Net Income TTM 2.76b / Total Stockholder Equity 14.0b)
RoCE = 21.47% (EBIT 7.35b / Capital Employed (Equity 14.0b + L.T.Debt 20.2b))
RoIC = 12.06% (NOPAT 5.11b / Invested Capital 42.3b)
WACC = 5.60% (E(93.0b)/V(118b) * Re(6.57%) + D(24.8b)/V(118b) * Rd(2.81%) * (1-Tc(0.31)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.25 | Cagr: 0.13%
[DCF] Terminal Value 77.97% ; FCFF base≈5.76b ; Y1≈6.61b ; Y5≈9.72b
[DCF] Fair Price = 589.9 (EV 146b - Net Debt 24.0b = Equity 122b / Shares 207.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -69.69 | EPS CAGR: -9.01% | SUE: 0.23 | # QB: 0
Revenue Correlation: 93.06 | Revenue CAGR: 5.30% | SUE: 1.15 | # QB: 1
EPS current Quarter (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-09-30): EPS=24.83 | Chg30d=-0.00% | Revisions=+0% | GrowthEPS=+39.8% | GrowthRev=+3.5%
EPS next Year (2027-09-30): EPS=26.05 | Chg30d=-0.05% | Revisions=+22% | GrowthEPS=+4.9% | GrowthRev=+6.8%
[Analyst] Revisions Ratio: +15% (up=6, down=4)